Pharma Research, Vaccine Nationalism and Sustainability in Times of Pandemic

Daniel Acquah
TIAS Postdoctoral Fellow


Sustainability and academic research, 4 June 2021





Happy families are all alike; every unhappy family is unhappy in its own way – Leo Tolstoy 1877
















Ebola Virus Disease (EVD)











Top 50 global pharmaceutical companies by prescription sales and R&D spending in 2019 (in billion U.S. dollars)

Top 50 pharmaceutical companies - Rx sales and R&D spending 2019





Note(s): Worldwide

Further information regarding this statistic can be found on <u>page 8</u>. **Source(s):** Pharmaceutical Executive; Evaluate; <u>ID 273029</u>








Global top 10 pharmaceutical companies based on projected R&D spending in 2026 (in billion U.S. dollars)

Global top pharmaceutical companies based on R&D spending 2026




Note(s): Worldwide; as of June 2020
Further information regarding this statistic can be found on page 8.
Source(s): Evaluate; ID 309469







statista 🔽



Inequity in Covid-19 vaccine deals

North American countries have purchased enough doses to fully vaccinate the region's population more than twice, while countries in Africa have only secured enough doses to cover a third of the continent's population.





In addition, the global **COVAX** program has purchased enough doses to inoculate 705 million people. The doses will be distributed among 190 participating countries, with the **aim to vaccinate 20% of the population in the 92 lower income countries**.

Source: Duke Global Health Innovation Center (Jan. 29, 2021); World Population Prospects 2019, United Nations; Gavi Graphic: Krystina Shveda and Henrik Pettersson, CNN





COXAX

CEPI





